Last reviewed · How we verify
NCT05451342
Explore Potential Plasma and BALF Immunometabolic and Lipidomic Biomarkers for Identifying ARDS Endotypes
trial testing Integrated Transcriptomics, Metabolomics, and Lipidomics Profiling in Acute Respiratory Distress Syndrome in 200 participants. Status unknown.
15 February 2024
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 15 February 2022 |
| Primary completion | 15 February 2024 |
| Estimated completion | 15 June 2024 |
| Sites | 2 locations across China |
Drugs / interventions tested
- Integrated Transcriptomics, Metabolomics, and Lipidomics Profiling
Conditions studied
- Acute Respiratory Distress Syndrome — all drugs for Acute Respiratory Distress Syndrome →
- Acute Respiratory Failure — all drugs for Acute Respiratory Failure →
Sponsor
Peking Union Medical College Hospital
Who can join
18 and older, any sex, with Acute Respiratory Distress Syndrome or Acute Respiratory Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acute respiratory distress syndrome (ARDS) is a life-threatening condition that causes high mortality (41% to 58%). Previous studies have reported that biomarkers can facilitate phenotypic diagnosis of ARDS, enabling precision treatment of ARDS. Although there were many studies that found some potential therapeutic targets for ARDS, no pharmacotherapies have been validated to treat ARDS. The development of biomarkers to predict the prognosis and monitor the response to treatment would be of interest for selecting patients for specific therapeutic trials. Many recent studies have shown that immune metabolic changes are involved in the pathogenesis of ARDS and may become a new therapeutic target for them. We aimed to identify a panel of immunometabolic and lipidomic biomarkers derived from blood and bronchoalveolar lavage fluid (BALF) which may help differentiate the ARDS endotypes.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Clinical applications of stem cell-derived exosomes.
Tan F, Li X, Wang Z, Li J, et al · · 2024 · cited 390× · PMID 38212307 · DOI 10.1038/s41392-023-01704-0 -
Exosomes─Nature's Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics.
Tenchov R, Sasso JM, Wang X, Liaw WS, et al · · 2022 · cited 336× · PMID 36354238 · DOI 10.1021/acsnano.2c08774 -
A critical systematic review of extracellular vesicle clinical trials.
Mizenko RR, Feaver M, Bozkurt BT, Lowe N, et al · · 2024 · cited 66× · PMID 39330928 · DOI 10.1002/jev2.12510 -
Advancements in extracellular vesicles biomanufacturing: a comprehensive overview of large-scale production and clinical research.
Li Z, Yan J, Li X, Chen H, et al · · 2025 · cited 7× · PMID 40046812 · DOI 10.3389/fbioe.2025.1487627 -
Potential of extracellular vesicles for early prediction of severity and potential risk stratification in critical inflammatory diseases.
Deng Y, Zou Y, Song X, Jiang A, et al · · 2023 · cited 3× · PMID 37195382 · DOI 10.1007/s12079-023-00763-w -
Effect Analysis of Extracellular Vesicles in the Treatment of Bronchopulmonary Dysplasia via Different Drug Delivery and Administration Routes.
Xu W, Chen S, Liang T, Kang L, et al · · 2025 · PMID 41019235 · DOI 10.2147/ijn.s530819
Verify or expand the search:
- PubMed search for NCT05451342
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Respiratory Distress Syndrome
Currently open trials in the same condition.
- NCT07284888 — Practices of Prone Positioning Ventilation in Patients With Moderate-to-Severe ARDS in Intensive Care Units: A Registry- · recruiting
- NCT07289711 — Validation and Precision Treatment of Inflammatory Subphenotypes in Acute Respiratory Distress Syndrome: A Multicenter C · recruiting
- NCT07326215 — A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+ · NA · recruiting
- NCT06919484 — The Physiological Effect of RCexp on Ventilation/Perfusion Distribution · recruiting
- NCT07126964 — Extended Prone Positioning for Intubated ARDS · NA · recruiting
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05451342 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 11 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05451342.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing